Bacteriophage Therapy for Catheter Infection Control
The primary aim of this project is to develop novel bacteriophage based strategies to combat Proteus mirabilis catheter associated urinary tract infection (CAUTI), a prevalent health-care associated infection for which there are c...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAFE CATHETER
Development of a cost effective anti bacterial device for th...
1M€
Cerrado
PID2020-112835RA-I00
HACIA UNA TERAPIA DE FAGOS CONTRA KLEBSIELLA PNEUMONIAE RESI...
184K€
Cerrado
SAF2017-82251-R
NUEVAS ESTRATEGIAS DE PREVENCION Y DIAGNOSTICO DE LAS INFECC...
133K€
Cerrado
PHAGOBURN
Evaluation of phage therapy for the treatment of Escherichia...
5M€
Cerrado
PID2020-117708GB-I00
CARACTERIZACION DE LOS MECANISMOS DE RESISTENCIA ADQUIRIDOS...
121K€
Cerrado
Información proyecto BATCIC
Líder del proyecto
UNIVERSITY OF BRIGHTON
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
1M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The primary aim of this project is to develop novel bacteriophage based strategies to combat Proteus mirabilis catheter associated urinary tract infection (CAUTI), a prevalent health-care associated infection for which there are currently no effective countermeasures. Indwelling urethral catheters (IUC) are the most commonly deployed medical devices, it is estimated that ~100 million IUC are used annually in healthcare systems globally, which equates to ~190 catheterisations per minute. However, IUC are vulnerable to infection, undermining their utility, jeopardising patient welfare and posing a substantial economic burden on healthcare systems. Over 40% of CAUTIs may be attributed to P. mirabilis, which poses particular problems in the care of catheterised patients. P. mirabilis causes encrustation and blockage of catheters, leading to serious complications such as pyelonephritis, septicaemia and shock. It is difficult to eliminate from the catheterised urinary tract, even after the catheter is removed, and often causes chronic infection recalcitrant to conventional antibiotic therapy. Given the prolific use of IUC and corresponding prevalence of CAUTIs in healthcare systems across the world, development of bacteriophage based strategies for control of CAUTIs would open a niche in a global market that is projected to reach an annual value of €2 billion by 2015.